EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Dual Antiplatelet Therapy Versus Direct Oral Anticoagulation in High‐Risk Patients Undergoing Left Atrial Appendage Occlusion With Watchman FLX

Abhinav Singh iD, Jeffrey P Steinhoff iD, Anton Lishmanov iD, Vivek Singh iD, Shaival Thakore, Suman Pasupuleti iD, Robert Subbiondo, Rias Ali iD, Ali Abdul Jabbar, Michael Moore, Olugbenga Oyesanmi iD, Anthony Furiato und 1 weitere

Journal of the American Heart Association · 12.11.2026

DOI: 10.1161/jaha.126.052169 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, online erschienen am 12.11.2026. Verfasst von Abhinav Singh und 12 weiteren Autor:innen. Beteiligte Einrichtung: HCA Bayonet Point Hospital Hudson FL USA. Hauptthemen laut MEDLINE: Left Atrial Appendage Closure, Platelet Aggregation Inhibitors, Atrial Fibrillation, Dual Anti-Platelet Therapy. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal antithrombotic therapy after left atrial appendage occlusion remains uncertain.

Methods

We studied 2817 patients undergoing left atrial appendage occlusion at 8 hospitals from 2016 to 2023 using registry data linked to Medicare claims. Among 2448 Watchman FLX recipients, the primary exposure was time‐varying dual antiplatelet therapy (DAPT) versus pooled direct oral anticoagulant (DOAC)‐based therapy. Outcomes were major adverse cardiovascular events (MACE), major bleeding, and device complications. The primary instrumental‐variable analysis used operator FLX preference; overlap weighting was secondary and pairwise regimen comparisons exploratory.

Results

DAPT was associated with lower MACE (absolute risk difference [ARD], −1.5% [95% CI, −1.9% to −1.0%]; number needed to treat, 67) and major bleeding (ARD −1.6% [95% CI, −2.0% to −0.9%]; number needed to treat, 63) than pooled DOAC‐based therapy, without increased device complications. Overlap‐weighted associations with MACE and major bleeding were nonsignificant. In exploratory pairwise analyses, DAPT did not differ significantly from DOAC monotherapy for MACE or major bleeding; lower major bleeding was limited to DAPT versus DOAC plus single antiplatelet therapy (ARD, −0.6% [95% CI, −1.1% to −0.2%]; P =0.008). Most estimated benefit accrued within 6 months.

Conclusions

DAPT was associated with lower MACE and major bleeding than pooled DOAC‐based therapy after Watchman FLX implantation. The safety benefit was concentrated in the comparison with DOAC + single antiplatelet therapy, whereas DAPT and DOAC monotherapy did not clearly differ in either outcome. These findings support randomized trials comparing DAPT with DOAC monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Left Atrial Appendage ClosurePlatelet Aggregation InhibitorsAtrial FibrillationDual Anti-Platelet TherapyFactor Xa InhibitorsStrokeAtrial AppendageHumansFemaleMaleAgedAdministration, OralHemorrhageAged, 80 and overRegistriesUnited StatesRisk FactorsTreatment OutcomeRetrospective StudiesRisk Assessment

Stichwörter der Autor:innen

Watchman FLXdirect oral anticoagulationdual antiplatelet therapyinstrumental variable analysisleft atrial appendage occlusion

Substanzen

Platelet Aggregation InhibitorsFactor Xa Inhibitors

Autor:innen und Institutionen

  • HCA Bayonet Point Hospital Hudson FL USA.
  • HCA Florida Largo Hospital Largo FL USA.
  • Kaiser Permanente Los Angeles Los Angeles CA USA.
  • HCA Florida Citrus Hospital Inverness FL USA.
  • HCA Florida Bradenton Hospital Bradenton FL USA.
  • HCA Florida Blake Hospital Bradenton FL USA.

ORCID-Profile: Abhinav Singh, Jeffrey P Steinhoff, Anton Lishmanov, Vivek Singh, Suman Pasupuleti, Rias Ali, Olugbenga Oyesanmi, Saurabh Sanon

Zitieren

APA

Singh, A., Steinhoff, J. P., Lishmanov, A., Singh, V., Thakore, S., Pasupuleti, S., Subbiondo, R., Ali, R., Abdul Jabbar, A., Moore, M., Oyesanmi, O., Furiato, A., & Sanon, S. (2026). Dual Antiplatelet Therapy Versus Direct Oral Anticoagulation in High‐Risk Patients Undergoing Left Atrial Appendage Occlusion With Watchman FLX. Journal of the American Heart Association. https://doi.org/10.1161/jaha.126.052169

Vancouver

Singh A, Steinhoff JP, Lishmanov A, Singh V, Thakore S, Pasupuleti S, et al. Dual Antiplatelet Therapy Versus Direct Oral Anticoagulation in High‐Risk Patients Undergoing Left Atrial Appendage Occlusion With Watchman FLX. Journal of the American Heart Association. 2026. doi:10.1161/jaha.126.052169

BibTeX
@article{Singh2026,
  author = {Singh, Abhinav and Steinhoff, Jeffrey P and Lishmanov, Anton and Singh, Vivek and Thakore, Shaival and Pasupuleti, Suman and Subbiondo, Robert and Ali, Rias and Abdul Jabbar, Ali and Moore, Michael and Oyesanmi, Olugbenga and Furiato, Anthony and Sanon, Saurabh},
  title = {Dual Antiplatelet Therapy Versus Direct Oral Anticoagulation in High‐Risk Patients Undergoing Left Atrial Appendage Occlusion With Watchman FLX},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.126.052169}
}
Kostenlos starten →